Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
Author:
Affiliation:
1. State Key Laboratory of Oncology in South China Guangzhou China
2. Collaborative Innovation Center for Cancer Medicine Guangzhou China
3. Department of Molecular Diagnostics Sun Yat‐sen University Cancer Center Guangzhou China
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4197
Reference28 articles.
1. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
2. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
3. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
5. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules;MedComm;2024-07-19
2. The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review;Journal of Cancer Metastasis and Treatment;2024-05-28
3. Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma;JAMA Network Open;2024-02-06
4. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study;BMC Cancer;2023-05-16
5. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data;Anticancer Research;2023-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3